小剂量罗红霉素联合不同药物治疗支气管扩张症的疗效观察

＋Clinical observation of small dose of roxithromycin combined with different drugs in treatment of bronchiectasis

目的 研究小剂量罗红霉素分别联合氨茶碱、沐舒坦在支气管扩张症中的治疗价值.方法 选择2012年3月至2013年12月我院收治的72例支气管扩张症患者为研究对象,按照入院顺序号随机分为治疗A组（36例）与治疗B组（36例）,治疗A组采用小剂量罗红霉素联合氨茶碱进行治疗,治疗B组则采用小剂量罗红霉素联合沐舒坦进行治疗.比较分析两组患者的治疗效果.结果 治疗A组患者的痰量明显少于治疗B组（t =2.569,P＜0.05）.治疗A组FEV1、FEV1/FVC等肺功能指标均显著优于治疗B组（t值分别为2.448、2.367,P值均＜0.05）.治疗A组的治疗总有效率为97.2％,治疗B组的治疗总有效率为83.3％,两组治疗总有效率比较差异有统计学意义（x2=0.518,P＜0.05）.治疗期间治疗A组急性加重致住院1例,出现不良反应1例;治疗B组急性加重致住院5例,出现不良反应4例.结论 小剂量罗红霉素联合氨茶碱治疗支气管扩张症疗效显著,值得临床推广与应用.

Objective To investigate clinical efficacy of small dose of roxithromycin combined with aminophylline and mucosolvan in the treatment of bronchiectasis.Methods 72 patients with bronchiectasis in our hospital from March 2012 to December 2013 were selected and randomly divided into the treatment group A （n =36） and treatment group B （n =36） according to the order of admission.The treatment group A received small dose of roxithromycin combined with aminophylline and the treatment group B was treated by small dose of roxithromycin combined with mucosolvan.The clinical efficacy of two groups was compared.Results The sputum volume of treatment group A was significantly lower than that of treatment group B （t =2.569,P 〈0.05）.The FEV1,FEV1/FVC improvement in lung function indicators of treatment group A were significantly better than those of the treatment group B （t =2.448,2.367,respectively,all P 〈0.05）.The total efficiency rate of the treatment group A was higher than that of the treatment group B （97.2% vs 83.3%,x2 =0.518,P 〈0.05）.During treatment,one case of hospitalization had acute exacerbation,one case had adverse reactions in treatment group A; five cases of hospitalization had acute exacerbation,four cases had adverse reactions in treatment group B.Conclusions Clinical efficacy of small dose of roxithromycin combined with aminophylline in the treatment of bronchiectasis is significant and it is worthy of promotion and application.